Bates S - Search Results

1

Dean M, Fojo T, Bates S. Dean M, et al. Among authors: bates s. Nat Rev Cancer. 2005 Apr;5(4):275-84. doi: 10.1038/nrc1590. Nat Rev Cancer. 2005. PMID: 15803154 Review.

2

Differential gene and microRNA expression between etoposide resistant and etoposide sensitive MCF7 breast cancer cell lines.

Moitra K, Im K, Limpert K, Borsa A, Sawitzke J, Robey R, Yuhki N, Savan R, Huang da W, Lempicki RA, Bates S, Dean M. Moitra K, et al. Among authors: bates s. PLoS One. 2012;7(9):e45268. doi: 10.1371/journal.pone.0045268. Epub 2012 Sep 18. PLoS One. 2012. PMID: 23028896 Free PMC article.

3

PolyHEMA spheroids are an inadequate model for the drug resistance of the intractable solid tumors.

Steadman K, Stein WD, Litman T, Yang SX, Abu-Asab M, Dutcher SK, Bates S. Steadman K, et al. Among authors: bates s. Cell Cycle. 2008 Mar 15;7(6):818-29. doi: 10.4161/cc.7.6.5597. Epub 2008 Jan 9. Cell Cycle. 2008. PMID: 18239467

4

Reversal of multidrug resistance: lessons from clinical oncology.

Bates SF, Chen C, Robey R, Kang M, Figg WD, Fojo T. Bates SF, et al. Novartis Found Symp. 2002;243:83-96; discussion 96-102, 180-5. Novartis Found Symp. 2002. PMID: 11990784 Review.

5

A Phase I study of infusional vinblastine in combination with the P-glycoprotein antagonist PSC 833 (valspodar).

Bates S, Kang M, Meadows B, Bakke S, Choyke P, Merino M, Goldspiel B, Chico I, Smith T, Chen C, Robey R, Bergan R, Figg WD, Fojo T. Bates S, et al. Cancer. 2001 Sep 15;92(6):1577-90. doi: 10.1002/1097-0142(20010915)92:6<1577::aid-cncr1484>3.0.co;2-h. Cancer. 2001. PMID: 11745237 Clinical Trial.

6

Enhanced adenovirus transgene expression in malignant cells treated with the histone deacetylase inhibitor FR901228.

Kitazono M, Goldsmith ME, Aikou T, Bates S, Fojo T. Kitazono M, et al. Among authors: bates s. Cancer Res. 2001 Sep 1;61(17):6328-30. Cancer Res. 2001. PMID: 11522619

7

Resistance to paclitaxel mediated by P-glycoprotein can be modulated by changes in the schedule of administration.

Zhan Z, Scala S, Monks A, Hose C, Bates S, Fojo T. Zhan Z, et al. Among authors: bates s. Cancer Chemother Pharmacol. 1997;40(3):245-50. doi: 10.1007/s002800050654. Cancer Chemother Pharmacol. 1997. PMID: 9219509

8

Generation of a drug resistance profile by quantitation of mdr-1/P-glycoprotein in the cell lines of the National Cancer Institute Anticancer Drug Screen.

Alvarez M, Paull K, Monks A, Hose C, Lee JS, Weinstein J, Grever M, Bates S, Fojo T. Alvarez M, et al. Among authors: bates s. J Clin Invest. 1995 May;95(5):2205-14. doi: 10.1172/JCI117910. J Clin Invest. 1995. PMID: 7738186 Free PMC article.

9

Initial pharmacokinetics and bioavailability of PSC 833, a P-glycoprotein antagonist.

Lush RM, Meadows B, Fojo AT, Kalafsky G, Smith HT, Bates S, Figg WD. Lush RM, et al. Among authors: bates s. J Clin Pharmacol. 1997 Feb;37(2):123-8. doi: 10.1002/j.1552-4604.1997.tb04770.x. J Clin Pharmacol. 1997. PMID: 9055138 Clinical Trial.

10

Characterization of oligomeric human half-ABC transporter ATP-binding cassette G2.

Xu J, Liu Y, Yang Y, Bates S, Zhang JT. Xu J, et al. Among authors: bates s. J Biol Chem. 2004 May 7;279(19):19781-9. doi: 10.1074/jbc.M310785200. Epub 2004 Mar 4. J Biol Chem. 2004. PMID: 15001581

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results